Zydus Cadila has received final approval from the USFDA to market Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Pre-filled Syringe (USRLD: Faslodex Injection). Fulvestrant injection is used alone or in combination with other drugs to treat a certain type of hormone receptor positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer that has spread to other parts of the body in women who have experienced menopause.
The drug will be manufactured at the group's formulation manufacturing facility at the Zydus Biologics, Ahmedabad. The group now has 320 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs. 585.95 as compared to the previous close of Rs. 571.9. The total number of shares traded during the day was 221450 in over 4878 trades.
The stock hit an intraday high of Rs. 594.45 and intraday low of 572.8. The net turnover during the day was Rs. 129481589.